Ultra-wide-field Fluorescein Angiography in Patients With Retinal Vein Occlusion

Launched by RENMIN HOSPITAL OF WUHAN UNIVERSITY · Aug 30, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a technique called ultra-wide-field fluorescein angiography (UWFA) to better understand and measure changes in eye conditions related to retinal vein occlusion (RVO). RVO is a condition where blood flow is blocked in the veins of the retina, which can lead to vision problems. The trial specifically looks at how UWFA can help assess issues like blood flow and leakage in the eye and how these factors might affect swelling in the central part of the retina (macular edema) and the growth of new blood vessels (neovascularization).

To participate in this trial, individuals must be at least 18 years old and have been diagnosed with one of three types of RVO (central, branch, or hemi-retinal) without any swelling in the retina. It's important that the condition has started within the last four months and that participants have not received any prior treatments for RVO. As part of the study, participants will undergo the UWFA procedure, which is a special imaging test that helps doctors see the blood vessels in the eye more clearly. The trial is currently recruiting participants, and those interested will need to provide written consent to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or female aged 18 years or more
• • 2. Patients with a diagnosis of CRVO,BRVO or HRVO without macular edema
• • 3. Duration of RVO not more than 4 months
• • 4. Naïve patients. Patient with previous RVO (more than 12 months before the inclusion date) which completely resolved (normalization of visual acuity and fundus examination) and who experienced a recurrence of RVO are also considered naive
• • 5. Patient who agrees to participate to the study and who has given his/her written, informed consent
• Exclusion Criteria:
• • 1. Patient with another retinal disease in the study eye: diabetic retinopathy, maculopathy of any cause (age-related macular degeneration, epimacular membrane, myopia, etc) responsible for decreased vision, advanced glaucoma, cataract severely affecting vision and/or requiring surgical treatment during the 24 months study period
• • 2. Active or suspected ocular or periocular infection
• • 3. Active severe intraocular inflammation
• • 4. RVO complicated with neovascularization
• • 5. Patient who has previously undergone laser panretinal photocoagulation, grid-laser or photodynamic therapy, any anti-VEGF or corticoids intravitreal injections in the study eye
• • 6. Patient already included in the study for the treatment of the fellow eye
• • 7. Pregnant or breastfeeding woman
• • 8. Lack of effective contraception for women of childbearing age
• • 9. Patient taking part in an interventional study